1422707-33-2

Upstream product

• 1223487-22-6 (13aR)-3-(benzyloxy)-6,7-dimethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione 
• 1223487-20-4 (2R)-1-{[3-(benzyloxy)-6,7-dimethoxy-9-phenanthryl]methyl}-5-oxopyrrolidine-2-carboxylic acid 
• 1422707-32-1 methyl (2R)-1-{[3-(benzyloxy)-6,7-dimethoxy-9-phenanthryl]methyl}-5-oxopyrrolidine-2-carboxylate 
• 26691-62-3 [3-(benzyloxy)-6,7-dimethoxy-9-phenanthryl]methanol 
• 26847-68-7 6,7-dimethoxy-3-benzoxy-9-phenanthrenecarboxylic acid methyl ester 
• 100-39-0 benzyl bromide 
• 1449298-72-9 3-hydroxy-6,7-dimethoxy-9-phenanthrenecarboxylic acid methyl ester 
• 1223487-24-8 C₂₉H₂₇NO₅ 

Downstream Products

• 1422707-35-4 (13aR)-3-(benzyloxy)-6,7-dimethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline 

Relevant academic research and scientific papers

Stereospecific synthesis and biological evaluation of monodesmethyl metabolites of (+)-13a-(S)-deoxytylophorinine as potential antitumor agents

Three major monodesmethyl metabolites of (+)-13a-(S)-deoxytylophorinine were synthesized stereospecifically and their configurations at C-13a were determined. Biological assays revealed that one of the metabolites, 3-O-desmethyl-13a-(S)-deoxytylophorinine

Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities

We previously reported that phenanthroindolizidine alkaloid 3 and its derivatives had markedly potent in vitro cytotoxicity. However, they had low in vivo antitumor activities and high in vivo toxicities, which was a serious problem. To address this probl